David Young - 06 Feb 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Pres. Research & Development, Director
Signature
/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
06 Feb 2024
Net transactions value
+$50,504
Form type
4
Filing time
07 Feb 2024, 16:22:44 UTC
Previous filing
12 Apr 2024
Next filing
08 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Purchase $50,504 +20,000 +52% $2.53 58,387 06 Feb 2024 Direct F1
holding PCSA Common Stock 30,985 06 Feb 2024 By Young-Plaisance Revocable Trust F1
holding PCSA Common Stock 10,786 06 Feb 2024 By Family Entities F1
holding PCSA Common Stock 18,544 06 Feb 2024 By CorLyst, LLC F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.